Etacillin — Competitive Intelligence Brief

Etacillin (HETACILLIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: hetacillin. Area: Infectious Disease.

marketed hetacillin Penicillin-binding protein Infectious Disease Small molecule

Target snapshot

Etacillin (HETACILLIN) — Bristol-Myers Squibb.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Etacillin TARGET	HETACILLIN	Bristol-Myers Squibb	marketed	hetacillin	Penicillin-binding protein	1982-01-01
CEFPIRAMIDE	CEFPIRAMIDE		marketed	cefpiramide	Bacterial penicillin-binding protein	1989-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
CEFMENOXIME	CEFMENOXIME		marketed	cefmenoxime	Bacterial penicillin-binding protein	1987-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	marketed	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Bl-S786R	CEFORANIDE		marketed	ceforanide	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1984-01-01
Cefobid	CEFOPERAZONE		marketed	Cephalosporin Antibacterial	Bacterial penicillin-binding protein, Penicillin-binding protein 1A	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (hetacillin class)

1. Bristol-Myers Squibb · 1 drug in this class